Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2025-09-28
Target enrollment:
Participant gender:
Summary
A multicenter, open, single arm, phase II clinical trial was designed for myometrial invasive
bladder cancer to evaluate the efficacy and safety of RC48-ADC combined with gemcitabine in
preoperative neoadjuvant treatment of MIBC, and provide high-level clinical evidence for
gemcitabine combined with ADC in the treatment of MIBC